Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
China
Harbin Medical University Cancer Hospital, Harbin, Heiljiang Province Liaoning Cancer Hospital, Shenyang, Liaoning